Overview
Novalis Biotech invests in innovative healthcare concepts from incorporation through Series A, with a focus on enabling technologies including research and manufacturing tools, bioinformatics, genomics, diagnostics, and digital health. The firm provides funding, professional and academic connections, and business strategy support to early-stage startups.
Key people
In the news
- Last week, Maria Fonseca joined #BostonBiotechWeek and #RESI in Boston on behalf of Obulytix, connecting with investors, biotech entrepreneurs, researchers, and industry leaders from across the life sciences ecosystem. A particular highlight was sharing the experience with the Belgian biotech delegation and exchanging perspectives on the challenges and opportunities of translating innovation from bench to patient in our local ecosystem. At RESI, organized by Life Science Nation, we gained valuable insights into US and
- Exciting milestone for myNEO Therapeutics! We are pleased to announce that Arcturus Therapeutics has entered into a definitive agreement to acquire myNEO. Since 2024, our teams have worked closely together around a shared vision: combining advanced AI capabilities with next generation mRNA innovation. We believe this combination creates a powerful foundation to accelerate discovery, strengthen target identification capabilities, and bring innovative therapies to patients faster. This achievement is the result of the hard work,
- 𝟭𝟬 𝘆𝗲𝗮𝗿𝘀, 𝟱,𝟬𝟬𝟬+ 𝗲𝗽𝗶𝗹𝗲𝗽𝘀𝘆 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀, 𝟯𝟮 𝗖𝗡𝗦 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝘁𝗿𝗶𝗮𝗹𝘀, 𝗮𝘁-𝗵𝗼𝗺𝗲 𝘃𝗘𝗘𝗚 𝗮𝗰𝗿𝗼𝘀𝘀 𝟰 𝗰𝗼𝗻𝘁𝗶𝗻𝗲𝗻𝘁𝘀, 𝗮𝗻𝗱 𝗺𝘂𝗰𝗵 𝗺𝗼𝗿𝗲... A decade ago, Clouds of Care started as a spin-off from Ghent University and the University of Antwerp, supported by imec. 🎂 We celebrated that journey the way it deserves: with a family day, inviting partners and children alongside our team to mark how far we've come! 🎉 Ten years of building EEG-based biomarkers for trials and
- It's not often that the good people of SynBioBeta mention work that one of our portfolio companies has done! A very big congratulations to the myNEO Therapeutics team!!
- Very good to see none other than Eric Topol confirming the business case for our portfolio company H42.ai (That said, many of his posts have a direct link to one or other of our portfolio companies.) H42 helps its customers analyse the meaning of epigenetic changes in relation to age related diseases in the broadest possible sense. They also get involved in the actual testing, as well as the development of biomarkers.
- When GSK commits $110M for biological data — not AI models — the message is clear. The headline: GSK-backed Relation Therapeutics launches a $110M deal and unveils MORGAN, a cell biology foundation model. The real story: GSK is paying for the PETASCALE cellular perturbation DATA that makes the model work. Not model licensing. Data manufacturing. At scale. Why does this matter? Because the bottleneck in AI drug discovery has shifted. We have enough models. What we don't have is training data that is: ✅ Homogeneous (not a
- myNEO in the news!
- The microcarrier market is booming — valued at $2.4-3.8B in 2026, projected to $5.5-14.9B by 2035 (11-16% CAGR). Cell and gene therapy manufacturing is the main driver, plus vaccine production and cell culture. Carroucell's sol-gel microcarrier technology is a genuinely differentiated play in this growing space — bioactive glass microstructures that can be functionalised for specific cell types, with validation from EFS (French Blood Establishment) and many others. They're competing with Cytiva, Sartorius, and Corning but with a
Related profiles
Something wrong or missing? Send an update. Fixed within 24 hours.